Suchergebnisse - "Camidge, D Ross"

PubPharm (348)

1

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer : KEYNOTE-782

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Bar, J. | Esteban, E. | Rodríguez-Abreu, D. | +20

2

Mobocertinib : Mechanism of action, clinical, and translational science

enthalten in: Clinical and translational science | 2024

von Hanley, M. | Camidge, D. | Fram, R. | +1

3

Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC

enthalten in: Clinical lung cancer | 2024

von Jennings, E. | Camidge, D. | Gadgeel, S. | +1

4

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

enthalten in: JTO clinical and research reports | 2024

von Patil, T. | Staley, A. | Nie, Y. | +19

5

CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression

enthalten in: Clinical lung cancer | 2024

von Jurica, J. | Carsten, B. | Balakhani, S. | +3

6

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Drilon, A. | Camidge, D. | Lin, J. | +131

7

Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancy

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Simons, E. | Camidge, D.

8

Mobocertinib : Mechanism of action, clinical, and translational science

enthalten in: Clinical and Translational Science | 2024

von Hanley, M. | Camidge, D. | Fram, R. | +1

9

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

enthalten in: Cancers | 2023

von Schreiber, A. | Kagihara, J. | Corr, B. | +16

10

Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

enthalten in: International journal of radiation oncology, biology, physics | 2023

von Wu, T. | Stube, A. | Felix, C. | +17

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[35]